DexCom's results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-29. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $1,344 million (+11.2% vs a year earlier) |
| Diluted EPS (GAAP) | $0.72 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $0.73 |
| Full-year guidance | Raised |
Guidance
Dexcom raised the midpoint of FY2026 revenue guidance, now $5.20–$5.25 billion, reiterated gross margin, and increased operating and EBITDA margin guidance.
Why this label: 'raising the midpoint of fiscal year 2026 Revenue guidance' and increasing operating/EBITDA margin guidance; gross margin reiterated; nothing core lower.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| revenue | FY2026 | $5.20–$5.25 billion (approx. 12–13% growth) | not stated |
| non-GAAP gross profit margin | FY2026 | approximately 64% | not stated |
| non-GAAP operating margin | FY2026 | approximately 24% | not stated |
| adjusted EBITDA margin | FY2026 | approximately 32% | not stated |
From the release
Revenue: "Revenue · $ · 1,344.5 · $ · 1,209.3"
Earnings per share: "GAAP net income was $275.1 million, or $0.72 per diluted share, for the third quarter of 2026, compared to GAAP net income of $283.8 million, or $0.70 per diluted share, for the third quarter of 2025. Non-GAAP net income* was $275.0 million, or $0.73 per diluted share"
revenue: "Revenue of $5.20 - $5.25 billion (approximately 12-13% growth)"
non-GAAP gross profit margin: "Non-GAAP Gross Profit Margin of approximately 64%"
non-GAAP operating margin: "Non-GAAP Operating Margin of approximately 24%"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Revenue grew 11% to $1.344 billion; FY2026 revenue and margin guidance raised
Source
DexCom earnings release (SEC filing), accession 0001093557-26-000193, filed 2026-10-29.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.